International bodies are offering true research opportunities, but African funding is needed to prepare the ground, writes Linda Nordling.

TB is linked with a deadly silicosis epidemic hidden for decades in rural South Africa. Gold mining firms must make amends, says Jaine Roberts.

New approaches are needed to reverse the trend of disappointing vaccines against HIV/AIDS, tuberculosis and malaria, argues biotech expert Thomas Egwang.

There is a pressing need for Africa to bolster its pharmaceuticals industry, and that requires the right policy framework, argues Priya Shetty.

Christian Lienhardt and colleagues outline where research and innovation must advance to meet the goal of eliminating tuberculosis.

Commercial antibody blood tests for TB have been declared ineffective by the WHO, but it is up to governments to halt their use, writes epidemiologist and TB researcher Madhukar Pai.

Nanomedicine requires careful development, not a great rush to jump on the bandwagon, argues nanotech expert Manoj Varma.

Malaria researchers must join forces to present a clear and detailed call for the resources they need, say Ian Boulton and Steve Ward.

Priya Shetty discusses why biomedical research is vital in steering progress towards the Millennium Development Goals.

A partnership involving the US Food and Drug Administration may speed up delivery of new tuberculosis drug combinations, says Priya Shetty.

Researchers and donors are not giving nutrition the attention it deserves, says Priya Shetty.

Micronutrients help fight disease — it's time to turn knowledge into action, say nutrition researchers Andrew Thorne-Lyman and Wafaie Fawzi.

A Peruvian clinic's treatment of extensively drug-resistant tuberculosis is an example to the developing world, says Mario C. Raviglione.

Multidrug-resistant TB needs more research to equip healthcare workers with the right tools, write Frank G. J. Cobelens and colleagues.

Non-communicable disease treatment has a lot to learn from tuberculosis control programmes, say Anthony D. Harries and colleagues.

More research is needed to see whether the success of the WHO's tuberculosis programme is at risk, say G. E. Davies and S. B. Squire.

Revised HIV/AIDS figures are a sign of better data, not that the epidemic is slowing. There is still much to be done, says Kevin De Cock.

The best way for European countries to combat tuberculosis is to help developing countries first, say Bruce Currey and colleagues.

Science needs to be injected into the controversy over use of nutritional supplements in tackling HIV and tuberculosis, says Wieland Gevers.